Why is Alkem Laboratories Ltd falling/rising?

Recent Price Movement and Market Context

On 01-Feb, Alkem Laboratories Ltd’s shares fell by ₹96.65, marking a 1.7% drop by 8:43 PM. This decline is part of a broader short-term weakness, with the stock having lost 3.1% over the past four consecutive trading days. The intraday low touched ₹5,513.95, representing a 2.8% dip from recent levels. This underperformance is notable when compared to the sector, as the stock lagged by 1.23% on the day.

Despite this short-term softness, the stock remains above its 200-day moving average, signalling that the longer-term trend is still intact. However, it is currently trading below its 5-day, 20-day, 50-day, and 100-day moving averages, indicating some near-term selling pressure and potential resistance levels that investors are watching closely.

Investor participation has been rising, with delivery volumes on 30 Jan increasing by 6.36% compared to the five-day average, suggesting heightened trading activity amid the recent price fluctuations. Liquidity remains adequate, supporting trades up to approximately ₹1.37 crore based on 2% of the five-day average traded value.

Long-Term Performance and Valuation Metrics

While the recent price action has been negative, Alkem Laboratories has demonstrated strong market-beating returns over longer periods. The stock has delivered a 9.66% return over the past year, outperforming the Sensex’s 5.16% gain. Over three and five years, the stock’s returns of 85.42% and 85.64% respectively have significantly outpaced the Sensex’s 35.67% and 74.40% gains. This consistent outperformance highlights the company’s resilience and growth potential.

From a valuation standpoint, the company maintains a fair price-to-book value of 5, supported by a return on equity (ROE) of 17.6%. This ROE reflects efficient management and profitability, further underscored by a low average debt-to-equity ratio of zero, indicating a conservative capital structure with minimal leverage risk. Profit growth over the past year has been steady at 7.8%, although the price-to-earnings-to-growth (PEG) ratio of 3.6 suggests that the stock is priced with expectations of continued growth, which may temper near-term price momentum.

Institutional investors hold a significant 31.51% stake in Alkem Laboratories, signalling confidence from sophisticated market participants who typically conduct thorough fundamental analysis. This institutional backing often provides a stabilising influence on the stock, even amid short-term volatility.

Balancing Short-Term Weakness with Long-Term Strength

The recent decline in Alkem Laboratories’ share price appears to be driven primarily by short-term market dynamics rather than fundamental deterioration. The stock’s underperformance relative to the sector and its own moving averages suggests profit-taking or cautious positioning by traders. However, the company’s strong management efficiency, demonstrated by a high ROE of 16.90%, and its conservative financial leverage provide a solid foundation for future growth.

Moreover, the stock’s ability to outperform broad market indices over multiple time horizons indicates that investors have rewarded its consistent earnings growth and operational stability. The rising delivery volumes hint at increased investor interest, which could support a recovery once short-term pressures ease.

In summary, while Alkem Laboratories Ltd is experiencing a temporary pullback in its share price as of 01-Feb, its robust fundamentals, fair valuation, and strong institutional support suggest that the stock remains well-positioned for long-term investors. Market participants should weigh the recent price softness against the company’s proven track record and financial health before making investment decisions.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →